BX-795

Catalog No.S1274

Molecular Weight(MW): 591.47

BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.

Cited by 10 Publications

Nature, 2019, 567(7747):262-266

PubMed: 30842662 ( click the link to review the publication )

Cell, 2019, 176(6):1447-1460

PubMed: 30799039 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(49):17438-43

PubMed: 25326420 ( click the link to review the publication )

J Thromb Haemost, 2018, 16(6):1211-1225

PubMed: 29575487 ( click the link to review the publication )

J Immunol, 2016, 196(5):2272-82

PubMed: 26826240 ( click the link to review the publication )

FEBS J, 2014, 281(17):3816-27

PubMed: 25040165 ( click the link to review the publication )

Virology, 2014, 450-451:182-95

PubMed: 24503081 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112014

PubMed: 25390891 ( click the link to review the publication )

J Biomol Screen, 2016, 10.1177/1087057116656314

PubMed: 27358388 ( click the link to review the publication )

4 Customer Reviews

(A) Washed human platelets were untreated or pretreated with the PDK1 inhibitor BX-795 (1 μM) for 5 min, and this was followed by stimulation with 2-methylthio-ADP (2MeSADP) (50 nM) under stirring for 5 min. Western blots were then probed for phosphorylated Akt (Thr308), Akt (Ser473), glycogen synthase kinase 3b (GSK3b) (Ser9), mitogen-activated protein kinase kinase 1/2 (MEK1/2) (Ser217/221), extracellular signal-regulated kinase 1/2 (ERK1/2) (Thr202/Tyr204), and cytosolic phospholipase A2 (cPLA2) (Ser505). The western blots shown are representative of three independent experiments.

J Thromb Haemost, 2018, 16(6):1211-1225. BX-795 purchased from Selleck.

Induction of basal p62 Ser403 phosphorylation in ULK1/2-deﬁcient MEF was suppressed by BX-795, an inhibitor of TBK1. WT ( Ulk1 +/+/Ulk2 +/+) and Ulk1 -/- /Ulk2 -/-(KO) MEF were treated with NaCl/Pi (Con) or 10 uM BX-795 for 6 h, and subjected to immunoblotting with indicated antibodies.

FEBS J 2014 281(17), 3816-27. BX-795 purchased from Selleck.
Virology 2014 450-451, 182-95. BX-795 purchased from Selleck.

Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 3.33 μM or 10 μM inhibitors (BX795 or CCT128930) in three-dimensional cell culture for 24 hours. Ten percent fetal bovine serum was used in A and B.

PLoS One, 2016, 11(5):e0155052. . BX-795 purchased from Selleck.

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Description

Targets

PDK-1 ^[1] (Cell-free assay)	c-Kit ^[1] (Cell-free assay)	CDK2/CyclinE ^[1] (Cell-free assay)	Chk1 ^[1] (Cell-free assay)
6 nM	320 nM	430 nM	510 nM

In vitro

BX-795 effectively blocks PDK1 activity in PC-3 cells, as shown by their ability to block phosphorylation of S6K1, Akt, PKCδ, and GSK3β. BX-795 potently inhibits tumor cell growth on plastic with IC50 of 1.6, 1.4, and 1.9 μM for MDA-468, HCT-116 and MiaPaca cells, respectively. In soft agar, BX-795 displays higher growth inhibition with IC50 of 0.72, and 0.25 μM for MDA-468, and PC-3 cells, respectively. ^[1] In addition, BX-795, as an inhibitor of the TBK1/IKKɛ, blocks TBK1- and IKKε-mediated activation of IRF3 and production of IFN-β. ^[2] In platelet physiological responses, BX795 produces inhibitory effect on 2-MeSADP-induced or collagen-induced aggregation, ATP secretion and thromboxane generation. ^[3]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human MV-4-11 cell	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3XQVmlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM3Njhibl2=	NV3kTpJ[W0GQR1XS
KRX cells	M4[5dmZ2dmO2aX;uJIF{e2G7	NFnVfVM4KG2rboO=	NHjZXYJKdmirYnn0bY9vKG:oIGPVUW8ufGGpZ3XkJHVNUzFiKIXub45wf25ib4Lp[4lvMSCtaX7hd4Uh\G:vYXnuJIV5eHKnc4Pl[EBqdiCNUmigZ4VtdHNidYPpcochYzN{UG2t[4FudWFvQWTQJIFv\CCveXXsbY4h[mG\|aXOgdJJwfGWrbjDzeYJ{fHKjdHWgbY5kfWKjdHXkJIZweiB5IH3pcpM>	MVWyOlI4PTZ6MR?=
human NKM-1 cell	NYT2c5B4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVnJcohq[mm2aX;uJI9nKGi3bXHuJG5MVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6zOlE6PCEQvF2=	MkSwV2FPT0WU
human P30-OHK cell	M{jORmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUTlSo1CUW6qaXLpeIlwdiCxZjDoeY1idiCSM{CtU2hMKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImsJGlEPTB;MD60PVY2KM7:TR?=	NEPSfGJUSU6JRWK=
human YH-13 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4DweWlvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlYzQDh6IN88US=>	Ml\LV2FPT0WU
human LXF-289 cell	M4rMVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2e4TmlvcGmkaYTpc44hd2ZiaIXtZY4hVFiILUK4PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NiCLQ{WwQVAvPjV4OUOg{txO	MoHNV2FPT0WU
human BE-13 cell	NHfTdYJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkTzTY5pcWKrdHnvckBw\iCqdX3hckBDTS1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuO\|A1PzdizszN	NYrTU5NXW0GQR1XS
human RS4-11 cell	MoL5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYL4VWZyUW6qaXLpeIlwdiCxZjDoeY1idiCUU{StNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd{NUm0JO69VQ>?	NXXtS5dzW0GQR1XS
human A3-KAW cell	M{KyOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml\1TY5pcWKrdHnvckBw\iCqdX3hckBCOy2NQWegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc{ODV3IN88US=>	MXTTRW5ITVJ?
human PA-1 cell	NWC0fmM1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHzHOHBKdmirYnn0bY9vKG:oIHj1cYFvKFCDLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlgxPDJ{IN88US=>	M1rPOnNCVkeHUh?=
human ES7 cell	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVrtXFVVUW6qaXLpeIlwdiCxZjDoeY1idiCHU{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg{PTZ4IN88US=>	NV7IenJnW0GQR1XS
human ES8 cell	M2PsT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlPyTY5pcWKrdHnvckBw\iCqdX3hckBGWzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki0N\|M3KM7:TR?=	M4nqRXNCVkeHUh?=
human SW982 cell	NW[5[ncyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGTkPHFKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PTF{NDFOwG0>	MYnTRW5ITVJ?
human VA-ES-BJ cell	NHPSWIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHnCVVVKdmirYnn0bY9vKG:oIHj1cYFvKF[DLVXTMWJLKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57OES2O{DPxE1?	NUnsSmZuW0GQR1XS
human 697 cell	M{HBSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mk\VTY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkCxOlI{KM7:TR?=	MU\TRW5ITVJ?
human MOLT-4 cell	M2LpWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUnJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFMzPDRizszN	NEjIfHFUSU6JRWK=
human D-283MED cell	M2WyXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3rwN2lvcGmkaYTpc44hd2ZiaIXtZY4hTC1{OEPNSWQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjB\|OUS4JO6ddQ>?	MlnrV2FPT0WU
human ALL-PO cell	M{PMfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFHq[\|RKdmirYnn0bY9vKG:oIHj1cYFvKEGOTD3QU{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODZyN{Og{txO	M1zKVHNCVkeHUh?=
human NB14 cell	NGnFOo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmnRTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6wOlA5OSEQvF2=	MWTTRW5ITVJ?
human NTERA-S-cl-D1 cell	M{W2cmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlWzTY5pcWKrdHnvckBw\iCqdX3hckBPXEWUQT3TMYNtNURzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6wO\|c4PSEQvF2=	NUeyN5d[W0GQR1XS
human BFTC-905 cell	Mlv5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGHvWm5KdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5yOEGwNUDPxE1?	NVXJe25HW0GQR1XS
human H4 cell	M{fUVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mnf6TY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwMUCyNFEh\|ryP	Mk\MV2FPT0WU
human CHP-212 cell	NX62O29yT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnHHTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yPDB\|NzFOwG0>	MlzZV2FPT0WU
human A204 cell	M2DhT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mm[xTY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6xOVQ3PyEQvF2=	NF;5VJpUSU6JRWK=
human NB69 cell	NEjIW\|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXzHbpFKUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yPTh4NTFOwG0>	NHrBVYtUSU6JRWK=
human P12-ICHIKAWA cell	M{jlUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUi4V2h[UW6qaXLpeIlwdiCxZjDoeY1idiCSMUKtTWNJUUuDV1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlE5OTdzIN88US=>	NEKzenJUSU6JRWK=
human L-363 cell	Mof2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmPYTY5pcWKrdHnvckBw\iCqdX3hckBNNTN4MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNVgyQTdizszN	NGHpfGRUSU6JRWK=
human ES5 cell	M3z4emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUfJcohq[mm2aX;uJI9nKGi3bXHuJGVUPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwMUmzOVQh\|ryP	NEXqfotUSU6JRWK=
human CAL-51 cell	Mn7SS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NV3NV2RZUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ{MUW2JO69VQ>?	NXm3VplIW0GQR1XS
human NBsusSR cell	MlHrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NF7CUIpKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ2NUe4JO69VQ>?	MX\TRW5ITVJ?
human HOP-92 cell	M2\ldGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NF\RfYRKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD25NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjd{OUOg{txO	MV3TRW5ITVJ?
human DU-4475 cell	M1fCNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnroTY5pcWKrdHnvckBw\iCqdX3hckBFXS12NEe1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zQTJ2NTFOwG0>	NVXFdYNGW0GQR1XS
human LB1047-RCC cell	NX7xcXZST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ7MkixJO69VQ>?	NWTPSHhSW0GQR1XS
human D-566MG cell	NGfTO2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWrDU2p1UW6qaXLpeIlwdiCxZjDoeY1idiCGLUW2Om1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5\|MES0PEDPxE1?	M2P3THNCVkeHUh?=
human A375 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1S2TmlvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|A5PThizszN	NGHTPJdUSU6JRWK=
human ATN-1 cell	Ml3nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3m4VWlvcGmkaYTpc44hd2ZiaIXtZY4hSVSQLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM4OTh3IN88US=>	NYDOeHN2W0GQR1XS
human M059J cell	M{HieGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHewSVZKdmirYnn0bY9vKG:oIHj1cYFvKE1yNUnKJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{PzZ3MjFOwG0>	NETre5NUSU6JRWK=
human HSC-3 cell	NWHpRYZkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3jwWGlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ1OjB6IN88US=>	MWnTRW5ITVJ?
human DOHH-2 cell	NVG1bIw1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlmzTY5pcWKrdHnvckBw\iCqdX3hckBFV0iKLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ2QDF2IN88US=>	M17DNHNCVkeHUh?=
human G-402 cell	M1fk[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NW[zNow{UW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDZ3MkWg{txO	MXfTRW5ITVJ?
human LC-2-ad cell	NF;aSmVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGnLO5BKdmirYnn0bY9vKG:oIHj1cYFvKEyFLUKtZYQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjR5MUOyJO69VQ>?	MYDTRW5ITVJ?
human LOXIMVI cell	NFLNVGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVr3VYxmUW6qaXLpeIlwdiCxZjDoeY1idiCOT2jJUXZKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS53MEW1NkDPxE1?	NUjwblJMW0GQR1XS
human DK-MG cell	M3PncWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NX;p[m9XUW6qaXLpeIlwdiCxZjDoeY1idiCGSz3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTd{OUig{txO	M4XtU3NCVkeHUh?=
human HOS cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYPnNIVUUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU4OzB7IN88US=>	MmCyV2FPT0WU
human BHT-101 cell	MknlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUDJcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU4QDd5IN88US=>	MlHXV2FPT0WU
human U-2-OS cell	NGrnSVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NE\3[FJKdmirYnn0bY9vKG:oIHj1cYFvKFVvMj3PV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTh6ME[g{txO	NWDhTI82W0GQR1XS
human D-423MG cell	Ml\PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkLwTY5pcWKrdHnvckBw\iCqdX3hckBFNTR{M13HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43ODhyNjFOwG0>	NG\WbmZUSU6JRWK=
human AN3-CA cell	Ml\iS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NUDmN4p[UW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZ\|OUmxJO69VQ>?	MnTrV2FPT0WU
human TE-11 cell	NFfFdWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGjFeppKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43PTJ6IN88US=>	NEnhbJdUSU6JRWK=
human SK-NEP-1 cell	NXjCbJc6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkP0TY5pcWKrdHnvckBw\iCqdX3hckBUUy2QRWCtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjV\|N{[g{txO	M4n4SHNCVkeHUh?=
human MG-63 cell	NY\TbFB3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUfJcohq[mm2aX;uJI9nKGi3bXHuJG1INTZ\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT62PFU3PyEQvF2=	NYm5NnRrW0GQR1XS
human RH-1 cell	M3\YeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2\GbmlvcGmkaYTpc44hd2ZiaIXtZY4hWkhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuO\|AzPzRizszN	MVrTRW5ITVJ?
human MDA-MB-157 cell	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkGzTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS55MU[3OEDPxE1?	MV3TRW5ITVJ?
human A427 cell	NUL1V3ZiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NH7JPXRKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc{PTh7IN88US=>	M1:wNXNCVkeHUh?=
human ES1 cell	NYDtdZRPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVjJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwN{W0OVEh\|ryP	NHr1TJZUSU6JRWK=
human C32 cell	MnTxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHLL[4RKdmirYnn0bY9vKG:oIHj1cYFvKEN\|MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuO\|Y{QSEQvF2=	MXHTRW5ITVJ?
human LAMA-84 cell	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYfXe5h6UW6qaXLpeIlwdiCxZjDoeY1idiCOQV3BMVg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS55Nki3NkDPxE1?	NWLCfHNPW0GQR1XS
human YKG-1 cell	MnflS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{HvS2lvcGmkaYTpc44hd2ZiaIXtZY4hYUuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc4OTJ2IN88US=>	MVPTRW5ITVJ?
human NCI-H1048 cell	M2Oxc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmDUTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGwOFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjd6NUC5JO69VQ>?	MXHTRW5ITVJ?
human KS-1 cell	M2LRTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGtUNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkiyPVgh\|ryP	NIXNNGFUSU6JRWK=
human JVM-3 cell	MlnYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXzTSXhlUW6qaXLpeIlwdiCxZjDoeY1idiCMVl2tN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQDZ2OUGg{txO	NU\h[mF{W0GQR1XS
human GI-ME-N cell	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXrJcohq[mm2aX;uJI9nKGi3bXHuJGdKNU2HLV6gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg3PTNizszN	MWDTRW5ITVJ?
human GT3TKB cell	NXLibpExT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2O3OmlvcGmkaYTpc44hd2ZiaIXtZY4hT1R\|VFvCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45QTZ2MjFOwG0>	M1TxfHNCVkeHUh?=
human CHL-1 cell	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NV;YN3FSUW6qaXLpeIlwdiCxZjDoeY1idiCFSFytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQTJ\|N{mg{txO	NGDBTnhUSU6JRWK=
human CHP-134 cell	M3PtPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mn\mTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMUO0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46PDR4NzFOwG0>	MVrTRW5ITVJ?
human 8-MG-BA cell	NV7Ee3g{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4DONmlvcGmkaYTpc44hd2ZiaIXtZY4hQC2PRz3CRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQTV5NESg{txO	NUfoPVNGW0GQR1XS
human HO-1-N-1 cell	NWDjfpptT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXXJcohq[mm2aX;uJI9nKGi3bXHuJGhQNTFvTj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46PzFzNzFOwG0>	NXS2fGpnW0GQR1XS
human SW1088 cell	NVzOfVV3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXLJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPVk3PzNizszN	NUHlcnJSW0GQR1XS
human SW48 cell	M4HObGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUjJcohq[mm2aX;uJI9nKGi3bXHuJHNYPDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkCyNFY4KM7:TR?=	M1;wTHNCVkeHUh?=
human VM-CUB-1 cell	M3[0emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MofJTY5pcWKrdHnvckBw\iCqdX3hckBXVS2FVVKtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODRzMUmg{txO	NVW4O2NnW0GQR1XS
human COLO-800 cell	M3:3b2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mlf4TY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUiwNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODVzM{[g{txO	MY\TRW5ITVJ?
human TI-73 cell	M2nQd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3[wZmlvcGmkaYTpc44hd2ZiaIXtZY4hXElvN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlEyOzl7IN88US=>	MmfUV2FPT0WU
human HN cell	MonrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2PzcWlvcGmkaYTpc44hd2ZiaIXtZY4hUE5iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkGyNVk5KM7:TR?=	MX7TRW5ITVJ?
human DB cell	M2r3T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3PKV2lvcGmkaYTpc44hd2ZiaIXtZY4hTEJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkGyOlMyKM7:TR?=	MkD5V2FPT0WU
human Ca9-22 cell	NFf4[3ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIfLS5pKdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOTJ6NEeg{txO	M3\6dXNCVkeHUh?=
human A549 cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{XJRWlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNVM5ODhizszN	NE\ZTpJUSU6JRWK=
human KGN cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFPPWZFKdmirYnn0bY9vKG:oIHj1cYFvKEuJTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNlI2QTVizszN	NUS3Tm05W0GQR1XS
human BCPAP cell	NXO2RWtlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUXCUJY3UW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjNzNUig{txO	NGHxenlUSU6JRWK=
human Ramos-2G6-4C10 cell	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUnuS3N3UW6qaXLpeIlwdiCxZjDoeY1idiCUYX3vd{0zTzZvNFOxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjN5NUmg{txO	MYrTRW5ITVJ?
human OVCAR-5 cell	NG[zPFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MULJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI4PzN2IN88US=>	NXfrdoJZW0GQR1XS
human KG-1 cell	Ml;4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXe1[VV7UW6qaXLpeIlwdiCxZjDoeY1idiCNRz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zPzd7MjFOwG0>	NFXNTm5USU6JRWK=
human CAKI-1 cell	NHnN[YdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml[3TY5pcWKrdHnvckBw\iCqdX3hckBESUuLLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI5ODV6IN88US=>	Mk\TV2FPT0WU
human QIMR-WIL cell	MlvuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXv5fYZnUW6qaXLpeIlwdiCxZjDoeY1idiCTSV3SMXdKVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwMki3OFQh\|ryP	M3H5cXNCVkeHUh?=
human SW1710 cell	NYixU4t[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{XXfWlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zQTF2MjFOwG0>	NF;z[lZUSU6JRWK=
human SK-UT-1 cell	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NULoenlVUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5{OUOzPUDPxE1?	MVvTRW5ITVJ?
human IST-SL1 cell	M2TiUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYfJcohq[mm2aX;uJI9nKGi3bXHuJGlUXC2VTEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlMzOTd2IN88US=>	NIDldFZUSU6JRWK=
human SW962 cell	M1vPUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4nvSGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlM{PzV5IN88US=>	M2nudHNCVkeHUh?=
human EM-2 cell	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWjJcohq[mm2aX;uJI9nKGi3bXHuJGVONTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkO1N\|M4KM7:TR?=	NUO3dFlbW0GQR1XS
human D-263MG cell	MojGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXTJcohq[mm2aX;uJI9nKGi3bXHuJGQuOjZ\|TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlM5OzJ5IN88US=>	MonWV2FPT0WU
human T98G cell	NGjzdIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVf0cHJZUW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4{QDh3NzFOwG0>	MVXTRW5ITVJ?
human CTB-1 cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVLH[ZRzUW6qaXLpeIlwdiCxZjDoeY1idiCFVFKtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOzl5NkGg{txO	M2HYeHNCVkeHUh?=
human Hs-578-T cell	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWDJcohq[mm2aX;uJI9nKGi3bXHuJGh{NTV5OD3UJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41OTV6NzFOwG0>	MX;TRW5ITVJ?
human SF126 cell	NHPaOVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXKxblZMUW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDN4MkGg{txO	NIqwT3BUSU6JRWK=
human NCI-H460 cell	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNE[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41Ozl3NTFOwG0>	MYHTRW5ITVJ?
human NCI-H1755 cell	M2PDbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe1OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPTRyNEOg{txO	MYHTRW5ITVJ?
human HL-60 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXjJcohq[mm2aX;uJI9nKGi3bXHuJGhNNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj61OFE2QSEQvF2=	MnXJV2FPT0WU
human G-401 cell	Mny3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUjJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDBzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj61OlA6QSEQvF2=	MlnNV2FPT0WU
human AGS cell	NX3hT\|l2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIDWe4ZKdmirYnn0bY9vKG:oIHj1cYFvKEGJUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuOVYzPTdizszN	NUT6V4tZW0GQR1XS
human HuO9 cell	NEXaTphIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3uxdWlvcGmkaYTpc44hd2ZiaIXtZY4hUHWROTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuOVY1PTZizszN	NEfMNXVUSU6JRWK=
human MFE-280 cell	NEXhVI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWPTVFNsUW6qaXLpeIlwdiCxZjDoeY1idiCPRlWtNlgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53Nk[4OkDPxE1?	NV71R\|N{W0GQR1XS
human NCI-H292 cell	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXvJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42Pzd{MjFOwG0>	M2D1e3NCVkeHUh?=
human HuO-3N1 cell	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3n1fmlvcGmkaYTpc44hd2ZiaIXtZY4hUHWRLUPONUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPjB\|MEeg{txO	M37sPHNCVkeHUh?=
human ES3 cell	NYK1eW9xT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1naUGlvcGmkaYTpc44hd2ZiaIXtZY4hTVN\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj62NlI5PSEQvF2=	MlHTV2FPT0WU
human LB2241-RCC cell	M37VPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MoTpTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54OUC3PUDPxE1?	M3zmTnNCVkeHUh?=
human NCI-H1155 cell	NYnh[2ZmT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUG1OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPjl2MEWg{txO	NV3VSFZ5W0GQR1XS
human SW872 cell	MlruS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHNYQDd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj63NFY4PiEQvF2=	MkfxV2FPT0WU
human MHH-ES-1 cell	Ml75S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWHJcohq[mm2aX;uJI9nKGi3bXHuJG1JUC2HUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44OjZ\|MzFOwG0>	M4TFS3NCVkeHUh?=
human KYSE-150 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml31TY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUG1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPzJ7NzFOwG0>	M3rnXnNCVkeHUh?=
human MC-IXC cell	NHznb2pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4LDVmlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45QTV\|IN88US=>	NVrtb4hkW0GQR1XS
human HCC1187 cell	NXztNIlST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHHGb2FKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{GxPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjh7Nke3JO69VQ>?	M2nLVnNCVkeHUh?=
human UMC-11 cell	NFP3S5lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmDaTY5pcWKrdHnvckBw\iCqdX3hckBWVUNvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlkxPDd5IN88US=>	NEnnO2VUSU6JRWK=
human NB5 cell	NIHRdodIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmrSTY5pcWKrdHnvckBw\iCqdX3hckBPSjViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmzO\|E2KM7:TR?=	MnjJV2FPT0WU
human A2058 cell	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnTVTY5pcWKrdHnvckBw\iCqdX3hckBCOjB3ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPVc5PDRizszN	NFHhfphUSU6JRWK=
human Becker cell	MlTHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHX0c2xKdmirYnn0bY9vKG:oIHj1cYFvKEKnY3vldkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODFzMUKg{txO	Mk\iV2FPT0WU
human CAS-1 cell	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFfqNYNKdmirYnn0bY9vKG:oIHj1cYFvKEODUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOTV4OTFOwG0>	NIXXUHdUSU6JRWK=
human SW780 cell	Mof6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NV;JfpNFUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjV4MEmg{txO	MWLTRW5ITVJ?
human KM12 cell	NGjpSFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEi2OWpKdmirYnn0bY9vKG:oIHj1cYFvKEuPMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlMxOTN{IN88US=>	Ml6yV2FPT0WU
human PC-3 cell	MojWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFrwR5FKdmirYnn0bY9vKG:oIHj1cYFvKFCFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE4PDFzIN88US=>	NWi2NGkyW0GQR1XS
human A253 cell	NHqwW3lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVr5NpdHUW6qaXLpeIlwdiCxZjDoeY1idiCDMkWzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yQDh7MzFOwG0>	M17PPXNCVkeHUh?=
human NB10 cell	NYfXZnFJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1vqeWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNlI4PzNizszN	MnOxV2FPT0WU
human A172 cell	M1XHRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXPJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkS0OVch\|ryP	NGG4bI9USU6JRWK=
human A498 cell	NI[2bHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2D0N2lvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuOVY{QDNizszN	NX\RN\|Z1W0GQR1XS
human SW1573 cell	NW\yUmNLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUXJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTV5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uPVA1QTFizszN	NUf2O2JuW0GQR1XS
human 5637 cell	M3vqbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVjJcohq[mm2aX;uJI9nKGi3bXHuJFU3OzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16LkC3PVA1KM7:TR?=	M{X6[nNCVkeHUh?=
human A388 cell	NG\IcYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MT6xN\|k5KM7:TR?=	M3eyb3NCVkeHUh?=
human U251 cell	NUfn[ohOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVXZOXhTUW6qaXLpeIlwdiCxZjDoeY1idiCXMkWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlgvOTF5NTFOwG0>	MnLnV2FPT0WU

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:^[1]	+ Expand Kinase assays: PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.
Cell Research:^[1]	+ Expand Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells Concentrations: ~10 μM Incubation Time: 72 hours Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates. (Only for Reference)

Kinase Assay:^[1]

+ Expand

Kinase assays:

PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.

Cell Research:^[1]

+ Expand

Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells
Concentrations: ~10 μM
Incubation Time: 72 hours
Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (169.07 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG +2% Tween 80+ddH2O For best results, use promptly after mixing.	4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BX-795 SDF

Molecular Weight	591.47
Formula	C₂₃H₂₆IN₇O₂S
CAS No.	702675-74-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you suggest an in vivo formulation of S1274 for animal studies?
Answer:
We recommend to use the vehicle 2% DMSO+30% PEG +2% Tween 80+ddH2O for in vivo study.

PDK Signaling Pathway Map

Related PDK Products0

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
OSU-03012 (AR-12)

OSU-03012 (AR-12) is a potent inhibitor of recombinant PDK-1(phosphoinositide-dependent kinase 1) with IC50 of 5 μM in a cell-free assay and 2-fold increase in potency over OSU-02067.

Features:A derivative of celecoxib with 10-fold greater antitumor activity, but lacks celecoxib's COX-2 inhibitory activity.
BX-912

BX912 is a potent and specific PDK1 inhibitor with IC50 of 12 nM, 9- and 105- fold greater selectivity for PDK1 than PKA and PKC in cell-free assays, respectively. In comparison to GSK3β, selectivity for PDK1 is 600-fold.
GSK2334470

GSK2334470 is a novel PDK1 inhibitor with IC50 of ~10 nM in a cell-free assay, with no activity at other close related AGC-kinases.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.

Choose Your Country or Region

By Signaling Pathways

By product type

BX-795

Cited by 10 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BX-795 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PDK Signaling Pathway Map

Related PDK Products0

Choose Your Country or Region

By Signaling Pathways

By product type

BX-795

Cited by 10 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BX-795 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PDK Signaling Pathway Map

Related PDK Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)